The paper provides updated 2025 management guidelines from the Association of British Neurologists (ABN) for autoimmune myasthenia gravis (MG). The document outlines several key updates from previous 2015 guidelines, emphasizing new standard practices such as prescribing daily steroids and recommending early thymectomy for certain patient groups. It extensively details the diagnosis, initial treatment (like pyridostigmine and prednisolone protocols), and long-term immunosuppression, including the recommended early use of rituximab for generalized MG. Furthermore, the guidelines introduce information on novel targeted therapies like complement inhibitors and neonatal Fc gamma receptor blockers, alongside protocols for managing MG relapses, emergencies, and myasthenia in pregnancy.